CN103735863A - Traditional Chinese medicine composition for preventing and controlling radiation - Google Patents
Traditional Chinese medicine composition for preventing and controlling radiation Download PDFInfo
- Publication number
- CN103735863A CN103735863A CN201410022608.4A CN201410022608A CN103735863A CN 103735863 A CN103735863 A CN 103735863A CN 201410022608 A CN201410022608 A CN 201410022608A CN 103735863 A CN103735863 A CN 103735863A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- herba
- radix
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for preventing and controlling radiation, which is capable of effectively solving the problems of being low in immunity and damaged in hematopoietic function caused by long-time radiation. The technical scheme is as follows: the traditional Chinese medicine composition disclosed by the invention is prepared from the following bulk drugs by weight: 10-30 g of radix pseudostellariae, 5-15 g of fructus psoraleae, 10-30 g of the fruit of Chinese wolfberry, 5-30 g of dendrobe, 10-20 g of radix polygonati officinalis, 10-30 g of houttuynia cordata, 10-30 g of humifuse euphorbia herb, 10-30 g of Indian rorippa herb, 3-10 g of pseudo-ginseng, 10-30 g of caulis spatholobi, and 5-15 g of madder. The traditional Chinese medicine composition disclosed by the invention is obtained by the following steps of: mixing the bulk drugs together, immersing by using distilled water for 1 h, adding 4-6 times of water or ethanol with the volume concentration of 70% for each time, decocting for two times and each time for 70 min, mixing decoctions, filtering, and concentrating to obtain fluid extract with the relative density of 1.16 at 60 DEG C to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition for preventing and controlling radiation disclosed by the invention has definite curative effects for improving hematopoietic function damage caused by long-time radiation and increasing immunity; the traditional Chinese medicine composition is an innovation of radiation-proof drugs.
Description
Technical field
The present invention relates to medicine, particularly a kind of Chinese medicine composition of preventing and treating radiation.
Background technology
Along with nuclear technology developing rapidly in aspect application such as industry, medical science, life sciences, the chance that people contact with lonizing radiation is increasing, such as the extensive use of computer, mobile phone, TV, microwave oven etc., radiation is not affecting our modern day life all the time.At medical domain, radiodiagnosis and treatment are also widely used.Especially clinical tumor patient is carried out to the conventional means that radiotherapy has become oncotherapy.These have all increased the probability that medical personnel contact with lonizing radiation.
Accept for a long time the damage that radiation can cause a lot of organs and systems, accepting in a large number radiation even can induced tumor, cause senilism.And destroy hemopoietic system, reduce function of immune system, it is the modal toxicity of radiotherapy.The chemicals toxicity due to known some with radiation resistance is larger, and therefore studying the radiopharmaceutical that toxic and side effects is little seems very important.Therefore, the improvement of radiopharmaceutical is the problem of needing at present solution badly.
Summary of the invention
For above-mentioned situation, for solving the defect of prior art, the present invention's object is just to provide a kind of Chinese medicine composition of preventing and treating radiation, can effectively solve the hypoimmunity of accepting for a long time radiation and causing, the problem of hemopoietic function damage.
The technical scheme that the present invention solves is, this Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 10-30g, Fructus Psoraleae 5-15g, Fructus Lycii 10-30g, Herba Dendrobii 5-30g, Rhizoma Polygonati Odorati 10-20g, Herba Houttuyniae 10-30g, Herba Euphorbiae Humifusae 10-30g, Herba Rorippae 10-30g, Radix Notoginseng 3-10g, Caulis Spatholobi 10-30g and Radix Rubiae 5-15g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, add the ethanol that the water of material medicine 4-6 times weight or the volumetric concentration of 4-6 times of weight are 70% at every turn, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
Adopt conventional preparation technology, the application of Chinese medicine composition of the present invention in assisting the tablet of oncotherapy, granule, capsule, pill, oral liquid, any medicine of syrup.
The present invention is on liver and kidney tonifying, benefiting QI and nourishing blood medicine Radix Pseudostellariae, Fructus Psoraleae, Fructus Lycii, Caulis Spatholobi basis, add clearing away heat and promoting production of body fluid, blood circulation promoting and blood stasis dispelling Chinese Medicinal Houttuynia Cordata Thunb, Herba Euphorbiae Humifusae, Herba Rorippae, Herba Dendrobii, Rhizoma Polygonati Odorati, Radix Notoginseng, Caulis Spatholobi and Radix Rubiae, aspect the hemopoietic function damage causing in the long-term radiation of improvement, raising immunity, curative effect certainly, is the innovation on radiopharmaceutical.
The specific embodiment
Below in conjunction with embodiment, the specific embodiment of the present invention is described in further detail.
Embodiment 1
This Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 10g, Fructus Psoraleae 5g, Fructus Lycii 10g, Herba Dendrobii 5g, Rhizoma Polygonati Odorati 10g, Herba Houttuyniae 10g, Herba Euphorbiae Humifusae 10g, Herba Rorippae 10g, Radix Notoginseng 3g, Caulis Spatholobi 10g and Radix Rubiae 5g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the water that at every turn adds 4 times of weight of material medicine, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtains.
Embodiment 2
This Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 20g, Fructus Psoraleae 10g, Fructus Lycii 20g, Herba Dendrobii 18g, Rhizoma Polygonati Odorati 15g, Herba Houttuyniae 20g, Herba Euphorbiae Humifusae 20g, Herba Rorippae 20g, Radix Notoginseng 6g, Caulis Spatholobi 20g and Radix Rubiae 10g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the ethanol that the volumetric concentration that at every turn adds 5 times of weight of material medicine is 70%, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtains.
Embodiment 3
This Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 30g, Fructus Psoraleae 15g, Fructus Lycii 30g, Herba Dendrobii 30g, Rhizoma Polygonati Odorati 20g, Herba Houttuyniae 30g, Herba Euphorbiae Humifusae 30g, Herba Rorippae 30g, Radix Notoginseng 10g, Caulis Spatholobi 30g and Radix Rubiae 15g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the water that at every turn adds 6 times of weight of material medicine, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtains.
Embodiment 4
This Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 10-19g, Fructus Psoraleae 5-9g, Fructus Lycii 10-19g, Herba Dendrobii 5-17g, Rhizoma Polygonati Odorati 10-14g, Herba Houttuyniae 10-19g, Herba Euphorbiae Humifusae 10-19g, Herba Rorippae 10-19g, Radix Notoginseng 3-5g, Caulis Spatholobi 10-19g and Radix Rubiae 5-9g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the ethanol that the volumetric concentration that at every turn adds material medicine 4-6 times weight is 70%, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
Embodiment 5
This Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 21-30g, Fructus Psoraleae 11-15g, Fructus Lycii 21-30g, Herba Dendrobii 19-30g, Rhizoma Polygonati Odorati 16-20g, Herba Houttuyniae 21-30g, Herba Euphorbiae Humifusae 21-30g, Herba Rorippae 21-30g, Radix Notoginseng 7-10g, Caulis Spatholobi 21-30g and Radix Rubiae 11-15g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, add the ethanol that the water of material medicine 4-6 times weight or the volumetric concentration of 4-6 times of weight are 70% at every turn, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
The foregoing is only best case study on implementation of the present invention, is only illustrative for the purpose of the present invention, and nonrestrictive.Those skilled in the art is understood, and can carry out some to it and revise, but all will fall within the scope of protection of the present invention in the scope of the claims in the present invention.
The present invention has the effect of liver and kidney tonifying, benefiting QI and nourishing blood, clearing away heat and promoting production of body fluid, blood circulation promoting and blood stasis dispelling, can effectively improve hemopoietic function damage that long-term radiation causes, immunity degradation etc., curative effect is sure, through repeated tests, all obtained useful technique effect, correlation test data is as follows:
One, Antiradiation injury pharmacodynamic experiment
1. materials and methods
1.1 material
SPF level Kunming mouse, in age in 6-8 week, male, Mouse Weight is 18-22g, 50.
1.2 animal grouping and methods
Experiment is divided into Normal group, irradiation control group, Chinese medicine preparation high dose group of the present invention (TCM-H), middle dosage group (TCM-M), low dose group (TCM-L).The disposable total irradiation of 60Co gamma-rays, 3.2 seconds/cGy of close rate, irradiation field 25cm * 25cm, source-skin distance 80cm, exposure dose 6Gy.60Co γ respectively at experiment first day and the tenth day with same dose irradiation.After irradiation, mice is total to gastric infusion 20 days.Variable concentrations Chinese medicine preparation of the present invention (12,24,48g/kg) 0.2ml gavage, matched group is with 0.2ml normal saline gavage.Test the 20th day, detect each experimental index, finish experiment.
2. detect index
2.1 analysis on hemogram
With blood-counter system, measure leukocyte, erythrocyte and platelet count, and record result.
2.2 bone marrow nucleated cell countings
Get a side femur, clean with normal saline flushing, cut off two ends epiphysis, with No. 7 needle pierces femur ends, with PBS liquid, repeatedly rinse medullary cavity, until femur punching is white (at least 10 times).The bone marrow fluid of going out filters stand-by by No. 4 syringe needles.Get 0.5ml4% acetic acid and 0.5ml bone marrow fluid and be placed in another test tube and mix, place 2 minutes, again fully mix, then get a little and splash into counting chamber, count under the microscope nucleated cell.Number of nucleated cells (L)=4 large grid nucleated cell sum/4 * 104 * extension rate
2.3 thymus and spleen weight
Experiment finishes to get spleen, and analytical balance is weighed.Spleen index=spleen weight/body weight * 1000
2.4 statistical analysis
Experimental result all with
represent, adopt SPSS15.0 statistical package to carry out statistical analysis.Adopt one factor analysis of variance (ANOVA), between group, compare between two, adopt the check of LSD method, P < 0.05 has significance for difference.
3 results
The impact of 3.1 the present invention on radiation murine peripheral hemogram
Studies show that, the obvious reduction of irradiation control group leukocyte, erythrocyte and platelet and Normal group, each dosage group energy leukocyte increasing of the present invention, erythrocyte and platelet counts, with irradiation control group comparison, have remarkable statistical significance (P < 0.05).In Table 1.
The impact of table 1 the present invention on radiation murine peripheral hemogram
With model group comparison, * P < 0.05, * * P < 0.01
3.2 the present invention are heavy on radiation murine bone marrow nucleated cell number and mice spleen, the impact of spleen index
Spleen is maximum lymphatic organ, is also one of important peripheral immune organ, the killer cell that contains a large amount of T cell, natural killer cell and Lymphokine etc.Spleen is also haematogenous antigen to be produced to the place of immunne response, can synthesize and secrete as bioactive substances such as complement, IFN, and spleen weight and index and spleen index have reflected the immune state of body indirectly.Studies show that, irradiation control group mice spleen weighs and spleen index, bone marrow nucleated cell digital display work reduces, the present invention is high, in, after low dose group has significantly raise and irradiated, the spleen of mice weighs and spleen index, the present invention is high, middle dosage group and irradiation control group comparison, there is obvious statistical significance (P < 0.05), the present invention is low, middle dosage group and irradiation control group comparison, there is remarkable statistical significance (P < 0.05), high dose group of the present invention and irradiation control group comparison, have and significant difference (P < 0.01).In Table 2.
Table 2 the present invention is heavy on radiation murine bone marrow nucleated cell number and mice spleen, the impact of spleen index
With model group comparison, * P < 0.05, * * P < 0.01
Two, clinical experiment
1. materials and methods
1.1 material
Collect case 90 examples, be pathology and make a definite diagnosis tumor patient, all do not accept radiotherapy.Male 48 examples wherein, female's 42 examples; Nasopharyngeal carcinoma 15 examples, 20 cases of breast cancer, pulmonary carcinoma 33 examples, cerebral glioma 4 examples, the esophageal carcinoma 18 examples, age 30-75 year, average 54 years old.Karnofsky scoring >=60 minutes, without radiotherapy contraindication.Patient is divided into 2 groups at random, treatment group 44 examples, matched group 46 examples, two groups at equal no difference of science of statistics in aspect such as sex, age, the state of an illness.
1.2 therapeutic scheme
All patients accept radiotherapy, and radiotherapy technology comprises three dimensional conformal radiation therapy and conventional radiotheraphy, during all Patients Treated by Radiotherapies, without chemotherapy, immunization therapy or other Chinese medicine medicine for preventing, treat.Matched group: patient accepts radiation alone.Treatment group: on the basis for the treatment of of control group, it is oral that Chinese medicine composition of the present invention is pressed crude drug concentration 0.65-1.35g/ml water drug-decocting concentrating liquid 200ml, once a day, treats altogether 2 months.
1.3 observation index
Prosperous according to NCI-CTC[week border. practical Internal Medicine-Oncology is learned [M] .2 version. Beijing: People's Health Publisher, 2003:29.] grade scale observation leukopenia degree, detects T lymphocyte subsets situation before all patient treatments and after treatment.
1.4 statistical analysis
Experimental result all with
represent, adopt SPSS15.0 statistical package to carry out statistical analysis.Adopt one factor analysis of variance (ANOVA), P < 0.05 has significance for difference.
2 experimental results
The impact of 2.1 the present invention on radiotherapy patient leukopenia degree
Experimental result demonstration, treatment group is after improving radiotherapy aspect leukopenia degree, and its therapeutic effect is obviously better than matched group, and 2 groups relatively have remarkable significant difference.In Table 3.
Table 3 treatment group and matched group are to the comparison of radiotherapy patient leukopenia degree [example (%)]
Compare △ P<0.05 with matched group
The impact of 2.2 the present invention on radiotherapy patient T cell subsets
Originally studies show that, after treatment of control group, with this group before treatment, CD3 cell and CD4/CD8 ratio significantly reduce, and after prompting radiotherapy, Immune Function is low.And after treatment group treatment, with comparison after treatment of control group, CD3 cell proportion and CD4/CD8 ratio raise, significant difference is remarkable, has shown the facilitation that the present invention recovers body's immunity.In Table 4.
Table 4 liang group patient T cell subsets comparison
With this group before treatment, △ P < 0.05, △ △ P < 0.01; With comparison * P < 0.05 after treatment of control group, * * P < 0.01
Chinese medicine composition of the present invention has the effect of Antiradiation injury, improving the hemopoietic function damage that radiation causes, improves immunity of organisms aspect, and curative effect is sure, is the innovation on radiopharmaceutical, has actual clinical meaning.
Claims (7)
1. a Chinese medicine composition of preventing and treating radiation, it is characterized in that, this Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 10-30g, Fructus Psoraleae 5-15g, Fructus Lycii 10-30g, Herba Dendrobii 5-30g, Rhizoma Polygonati Odorati 10-20g, Herba Houttuyniae 10-30g, Herba Euphorbiae Humifusae 10-30g, Herba Rorippae 10-30g, Radix Notoginseng 3-10g, Caulis Spatholobi 10-30g and Radix Rubiae 5-15g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, add the ethanol that the water of material medicine 4-6 times weight or the volumetric concentration of 4-6 times of weight are 70% at every turn, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
2. the Chinese medicine composition of control radiation according to claim 1, it is characterized in that, this Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 10g, Fructus Psoraleae 5g, Fructus Lycii 10g, Herba Dendrobii 5g, Rhizoma Polygonati Odorati 10g, Herba Houttuyniae 10g, Herba Euphorbiae Humifusae 10g, Herba Rorippae 10g, Radix Notoginseng 3g, Caulis Spatholobi 10g and Radix Rubiae 5g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the water that at every turn adds 4 times of weight of material medicine, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
3. the Chinese medicine composition of control radiation according to claim 1, it is characterized in that, this Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 20g, Fructus Psoraleae 10g, Fructus Lycii 20g, Herba Dendrobii 18g, Rhizoma Polygonati Odorati 15g, Herba Houttuyniae 20g, Herba Euphorbiae Humifusae 20g, Herba Rorippae 20g, Radix Notoginseng 6g, Caulis Spatholobi 20g and Radix Rubiae 10g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the ethanol that the volumetric concentration that at every turn adds 5 times of weight of material medicine is 70%, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
4. the Chinese medicine composition of control radiation according to claim 1, it is characterized in that, this Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 30g, Fructus Psoraleae 15g, Fructus Lycii 30g, Herba Dendrobii 30g, Rhizoma Polygonati Odorati 20g, Herba Houttuyniae 30g, Herba Euphorbiae Humifusae 30g, Herba Rorippae 30g, Radix Notoginseng 10g, Caulis Spatholobi 30g and Radix Rubiae 15g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the water that at every turn adds 6 times of weight of material medicine, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
5. the Chinese medicine composition of control radiation according to claim 1, it is characterized in that, this Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 10-19g, Fructus Psoraleae 5-9g, Fructus Lycii 10-19g, Herba Dendrobii 5-17g, Rhizoma Polygonati Odorati 10-14g, Herba Houttuyniae 10-19g, Herba Euphorbiae Humifusae 10-19g, Herba Rorippae 10-19g, Radix Notoginseng 3-5g, Caulis Spatholobi 10-19g and Radix Rubiae 5-9g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, the ethanol that the volumetric concentration that at every turn adds material medicine 4-6 times weight is 70%, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
6. the Chinese medicine composition of control radiation according to claim 1, it is characterized in that, this Chinese medicine composition is the material medicine by following weighing scale: Radix Pseudostellariae 21-30g, Fructus Psoraleae 11-15g, Fructus Lycii 21-30g, Herba Dendrobii 19-30g, Rhizoma Polygonati Odorati 16-20g, Herba Houttuyniae 21-30g, Herba Euphorbiae Humifusae 21-30g, Herba Rorippae 21-30g, Radix Notoginseng 7-10g, Caulis Spatholobi 21-30g and Radix Rubiae 11-15g make, wherein, by above-mentioned raw materials medicament mixed together, with distilled water immersion 1 hour, add the ethanol that the water of material medicine 4-6 times weight or the volumetric concentration of 4-6 times of weight are 70% at every turn, decoct 2 times, each 70 minutes, merge 2 times decoction liquor, filter, the fluid extract that while being concentrated into 60 ℃, relative density is 1.16, obtain.
7. the application of the Chinese medicine composition of the control radiation described in claim 1 or 2-6 any one in assisting the tablet of oncotherapy, granule, capsule, pill, oral liquid, any medicine of syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410022608.4A CN103735863B (en) | 2014-01-16 | 2014-01-16 | A kind of Chinese medicine composition of preventing and treating radiation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410022608.4A CN103735863B (en) | 2014-01-16 | 2014-01-16 | A kind of Chinese medicine composition of preventing and treating radiation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735863A true CN103735863A (en) | 2014-04-23 |
| CN103735863B CN103735863B (en) | 2016-05-11 |
Family
ID=50492979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410022608.4A Expired - Fee Related CN103735863B (en) | 2014-01-16 | 2014-01-16 | A kind of Chinese medicine composition of preventing and treating radiation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735863B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491688A (en) * | 2014-12-02 | 2015-04-08 | 国家电网公司 | Preparation method of biological agent for preventing electromagnetic radiation |
| CN104491689A (en) * | 2014-12-02 | 2015-04-08 | 国家电网公司 | Ionization radiation injury protective agent |
-
2014
- 2014-01-16 CN CN201410022608.4A patent/CN103735863B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 张代钊等: "中医药防治研究放化疗毒副反应40年", 《中国自然医学杂志》, vol. 2, no. 2, 29 February 2000 (2000-02-29), pages 114 - 117 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491688A (en) * | 2014-12-02 | 2015-04-08 | 国家电网公司 | Preparation method of biological agent for preventing electromagnetic radiation |
| CN104491689A (en) * | 2014-12-02 | 2015-04-08 | 国家电网公司 | Ionization radiation injury protective agent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735863B (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109908302A (en) | A kind of Chinese medicine composition, preparation method and application inhibiting metastases | |
| CN104127808A (en) | Traditional Chinese medicinal preparation for treating malignant tumors, and preparation method thereof | |
| CN103735863B (en) | A kind of Chinese medicine composition of preventing and treating radiation | |
| CN104491689A (en) | Ionization radiation injury protective agent | |
| CN104491688A (en) | Preparation method of biological agent for preventing electromagnetic radiation | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| Lahans | Integrating conventional and Chinese medicine in cancer care: A clinical guide | |
| CN103816379B (en) | One is treated leukemic Chinese medicine composition and preparation method thereof | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN103705846A (en) | Traditional Chinese medicine preparation for treating ovarian cyst | |
| CN103599265B (en) | A kind of compound traditional Chinese medicine for radiation protection | |
| CN102258626A (en) | Traditional Chinese medicine compound Tenghuanglin, preparation method and application thereof | |
| CN105616633A (en) | Preparation method of traditional Chinese medicine composition for treating leukopenia after chemotherapy | |
| CN102139021A (en) | Chinese medicinal preparation for preventing and treating radiation and preparation method thereof | |
| CN102225182A (en) | Traditional Chinese preparation capable of inhibiting tumor and enhancing immunity and preparation method thereof | |
| CN102188592A (en) | Medicine for treating thrombocytopenia after tumor chemotherapy and preparation method thereof | |
| CN1108158C (en) | Analgesic composition | |
| CN107281212B (en) | A kind of jujube complex polysaccharide composition and its preparation method and application | |
| CN100337675C (en) | Chinese medicinal formulation for treating qi and blood deficiency caused by radiotherapy and chemotherapy for tumor and its preparation method | |
| CN106620435A (en) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof | |
| CN105521100A (en) | Traditional Chinese medicinal composition for treating leucopenia after chemotherapy | |
| CN107050373A (en) | A kind of medicament and preparation method for being used to treat the proliferation of mammary gland | |
| CN1066943C (en) | Oral liquor for curing cancer | |
| CN102727567B (en) | Chinese medicine composition with radiation protecting function | |
| CN104189846A (en) | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160511 Termination date: 20170116 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |